A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 02 Feb 2024
Price :
$35 *
At a glance
- Drugs Genistein (Primary) ; Carboplatin; Paclitaxel
- Indications Acute radiation syndrome; Radiation injuries
- Focus Adverse reactions
- Sponsors Humanetics Corporation
- 01 Feb 2024 Results evaluating the clinical utility of BIO 300 Oral Suspension in patients with NS, published in the International Journal of Radiation Oncology, Biology, Physics
- 19 Sep 2023 Positive clinical results presented in a Humanetics Corporation Media Release.
- 24 Nov 2020 Status changed from active, no longer recruiting to completed.